Dilated Cardiomyopathy (DCM) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Dilated Cardiomyopathy (DCM) Market Outlook

Thelansis’s “Dilated Cardiomyopathy (DCM) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Dilated Cardiomyopathy treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Dilated Cardiomyopathy (DCM) Overview

Dilated cardiomyopathy (DCM) is a pathological condition of the heart characterized by the dilation and enlargement of one or both ventricles, along with impaired contractility, as defined by a left ventricular ejection fraction (LVEF) of less than 40%. The condition can be classified as primary or secondary, with primary DCM being of idiopathic origin and diagnosed after excluding secondary causes. Patients with DCM typically have systolic dysfunction and may or may not exhibit overt symptoms of heart failure. DCM is often progressive, leading to heart failure and death. Without a transplant, survival rates for patients with DCM are poor. The etiology of DCM is diverse, with the most common cause being idiopathy, and may also have a familial or genetic predisposition. Secondary causes include infectious myocarditis, ischemic disease, hypertension, medication-induced alcohol abuse, HIV, peripartum cardiomyopathy, or infiltrative disease. The New York Heart Association (NYHA) classification of heart failure is often used to assess the severity of DCM. It includes four stages: Stage A (at-risk individuals), Stage B (asymptomatic left ventricular systolic dysfunction), Stage C (symptomatic heart failure), and Stage D (refractory end-stage heart failure). Overall, the prognosis for patients with DCM is guarded, with most patients eventually developing chronic heart failure. Negative prognostic factors include advanced NYHA classification, male sex, severe heart failure, and renal failure. Individuals with symptoms at rest and cannot exercise usually have the poorest prognosis. Optimal medical therapy can improve the quality of life for patients with mild heart failure.

• The estimated prevalences of approximately 1: 250-400 and up to 1: 2500 in the general population.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2022-2032

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: